

# Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults

NCT06815991

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1
<b>Sponsor</b>	Metro International Biotech, LLC
<b>Enrollment</b>	32 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Is a non-smoking healthy adult, 19 to 60 years of age, inclusive
- Has a body mass index (BMI) between 19 and 37.5 kg/m<sup>2</sup>, inclusive
- Is free from clinically significant medical problems as determined by the Investigator
- Is able and willing to provide written informed consent.
- Is able and willing to provide authorization for the use and disclosure of personal health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA).

### Exclusion (23)

- Is a current cigarette smoker
- AST or ALT  $\gt$  1.5 times the upper limit of normal
- Hematocrit  $\lt$  37% or  $\gt$  51%
- Diagnosis of diabetes mellitus, as indicated by use of diabetes medication, hemoglobin A1C  $\gt$  6.4% or fasting glucose  $\geq$  126 mg/dL
- Serum creatinine  $\gt$  2.0 mg/dL

... and 18 more (see full listing online)

## Locations (1 total)

---

Brigham and Women's Hospital, Boston, Massachusetts, United States